|  |  | Treatment Phase | Follow-up Phase | Long-Term Follow-up | |||
---|---|---|---|---|---|---|---|---|
Clinical Assessments, Testing and Investigations | Screening and Randomization | Baseline | Weeks 1 to 6 | End of Treatment | Weeks 6 to 12 | End of Follow-up | Week 30 | Week 52 |
Suitability for HBOT | X | Â | Â | Â | Â | Â | Â | Â |
Electrocardiogram | O | Â | Â | Â | Â | Â | Â | Â |
Pulmonary Function Testing | O | X | Â | Â | Â | Â | Â | Â |
Audiogram | O | Â | Â | Â | Â | Â | Â | Â |
Chest X-ray | O | Â | Â | Â | Â | Â | Â | Â |
X-ray of affected limb | O | X | Â | Â | Â | Â | Â | Â |
Nuclear bone scan | O | Â | Â | Â | Â | Â | Â | Â |
Vascular Exam | X | O | O | O | O | X | Â | Â |
History & Physical | Â | X | Â | Â | Â | Â | Â | Â |
Demographics | Â | X | Â | Â | Â | Â | Â | Â |
Treatment Details | Â | X | X | Â | Â | Â | Â | Â |
Wound Classifications (Wagner, Bates) | X | X | X | Â | X | Â | Â | Â |
Wound Measurements | Â | X | X | Â | X | Â | Â | Â |
Wound Characteristics | Â | X | X | Â | X | Â | Â | Â |
Digital Photograph of wound | Â | X | X | Â | X | Â | Â | Â |
Dressing Changes | X | X | X | Â | O | O | Â | Â |
Concomitant Meds | Â | X | X | Â | X | Â | Â | Â |
Assess for Infection | X | X | X | Â | X | Â | Â | Â |
Mobility Status | Â | X | X | Â | X | Â | Â | Â |
Adverse Events | Â | X | X | Â | X | Â | X | X |
Outcome Assessment | X | X | X | Â | X | Â | Â | Â |
Unblinding | Â | O | O | O | O | O | Â | Â |
Laboratories | X | X | Â | X | Â | X | Â | Â |
Resource Utilization | Â | X | X | Â | X | Â | X | X |
Quality of Life: | Â | Â | Â | Â | Â | Â | Â | Â |
SF-36 | Â | X | Â | X | Â | X | Â | Â |
EQ-5D | Â | X | Â | X | Â | X | X | X |
DFS-SF | Â | X | Â | X | Â | X | Â | Â |